Publication:
WUNDERLICH’S SYNDROME IN COVID-19 PATIENT

dc.contributor.authorOpancina, Miljan (57192909391)
dc.contributor.authorMijailovic, Zeljko (6506982098)
dc.contributor.authorVojinovic, Radisa (11640450400)
dc.contributor.authorSaponjski, Jovica (56629875900)
dc.contributor.authorTrivic, Vladimir (36996311900)
dc.contributor.authorOpancina, Valentina (57192906143)
dc.date.accessioned2025-06-12T12:21:01Z
dc.date.available2025-06-12T12:21:01Z
dc.date.issued2023
dc.description.abstractUp to this date, more than 180 million people worldwide have been affected with COVID-19 and more than 3.9 million people have died. The effect of COVID-19 on thrombosis is well known, and due to this, anticoagulant agents are prescribed. However, the use of anticoagulants is associated with the bleeding trend and occasionally major complications and death outcomes. In this paper, we present the case of a COVID-19 patient treated with anticoagulant therapy who developed Wunderlich’s syndrome. Up to our knowledge, this is the first case of this syndrome in a patient with COVID-19. © Experimental and Applied Biomedical Research.All rights reserved.
dc.identifier.urihttps://doi.org/10.2478/sjecr-2022-0042
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85181023058&doi=10.2478%2fsjecr-2022-0042&partnerID=40&md5=b1f2a77b4faf668c5d2ec1af2cc33828
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/2908
dc.subjectanticoagulants
dc.subjectCOVID-19
dc.subjectiliopsoas hematoma
dc.subjectretroperitoneal haemorrhage
dc.subjectWunderlich syndrome
dc.titleWUNDERLICH’S SYNDROME IN COVID-19 PATIENT
dspace.entity.typePublication

Files